CLINICAL & PIPELINE·Drug Approval
Moderna's mFlusiva Flu Vaccine Faces Intense FDA Scrutiny Ahead of Pivotal Advisory Panel Vote
Moderna's mFlusiva, an mRNA seasonal influenza vaccine, faces significant FDA scrutiny regarding its efficacy data, particularly for older and vulnerable populations. An advisory panel will vote on its benefit-risk profile this Thursday. This pivotal moment for Moderna's regulatory journey could reshape the competitive landscape for flu vaccines, impacting procurement and supply chain strategies for global health organizations and pharmaceutical distributors.
90-Day Activity